Efficacy of oral ciprofloxacin as selective intestinal decontaminant in cirrhosis

M. Borzio, F. Salerno, M. Saudelli, D. Galvagno, L. Piantoni, L. Fragiacomo

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background. Selective intestinal decontamination has been proposed to prevent bacterial infection in cirrhosis. Aims. To evaluate the efficacy of ciprofloxacin as selective intestinal decontaminant. Patients and methods. Quantitative microbiological studies on serial faeces were carried out in 15 cirrhotic patients. Ciprofloxacin was given orally at the starting dose of 250 mg every 12 hours for 7 days followed by a single dose of 250 mg/day from day 7 to day 14 and 125 mg/day for the next 3 weeks. Total stool samples were examined in basal conditions and on days 7, 14, 21, 28 and 35 of treatment and 3 and 7 days after treatment withdrawal. Results. Gram-negative flora was completely eliminated in all patients by ciprofloxacin given at doses of 500 and 250 mg/day. When the drug was tapered to 125 mg/day, Escherichia coli reappeared in stools of 7 patients (antibiotic resistant in one patient) and Klebsiella oxytoca in two patients (antibiotic-resistant in one patient). Faecal concentration of Group D Streptococcus was significantly increased at the end of therapy (basal mean 7.7 ± 1.2 log CFU vs post treatment mean 9.6 ± 0.5 log CFU, p <0.05) while the faecal concentration of anaerobic flora and Candida albicans showed no change. Conclusions. Results of this study demonstrate the efficacy of oral ciprofloxacin 250 mg/day is the recommended dose for maintaining Selective Intestinal Decontamination. However, the risks of inducing antibiotic resistance in Gram-positive flora and promoting overgrowth of Gram-positive flora must be carefully considered in all patients chronically treated with oral quinolones.

Original languageEnglish
Pages (from-to)262-266
Number of pages5
JournalItalian Journal of Gastroenterology and Hepatology
Volume29
Issue number3
Publication statusPublished - 1997

Fingerprint

Ciprofloxacin
Fibrosis
Decontamination
Klebsiella oxytoca
Anti-Bacterial Agents
Enterococcus faecalis
Quinolones
Therapeutics
Microbial Drug Resistance
Candida albicans
Bacterial Infections
Feces
Escherichia coli
Pharmaceutical Preparations

Keywords

  • Ciprofloxacin
  • Cirrhosis
  • Intestinal decontamination

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Borzio, M., Salerno, F., Saudelli, M., Galvagno, D., Piantoni, L., & Fragiacomo, L. (1997). Efficacy of oral ciprofloxacin as selective intestinal decontaminant in cirrhosis. Italian Journal of Gastroenterology and Hepatology, 29(3), 262-266.

Efficacy of oral ciprofloxacin as selective intestinal decontaminant in cirrhosis. / Borzio, M.; Salerno, F.; Saudelli, M.; Galvagno, D.; Piantoni, L.; Fragiacomo, L.

In: Italian Journal of Gastroenterology and Hepatology, Vol. 29, No. 3, 1997, p. 262-266.

Research output: Contribution to journalArticle

Borzio, M, Salerno, F, Saudelli, M, Galvagno, D, Piantoni, L & Fragiacomo, L 1997, 'Efficacy of oral ciprofloxacin as selective intestinal decontaminant in cirrhosis', Italian Journal of Gastroenterology and Hepatology, vol. 29, no. 3, pp. 262-266.
Borzio M, Salerno F, Saudelli M, Galvagno D, Piantoni L, Fragiacomo L. Efficacy of oral ciprofloxacin as selective intestinal decontaminant in cirrhosis. Italian Journal of Gastroenterology and Hepatology. 1997;29(3):262-266.
Borzio, M. ; Salerno, F. ; Saudelli, M. ; Galvagno, D. ; Piantoni, L. ; Fragiacomo, L. / Efficacy of oral ciprofloxacin as selective intestinal decontaminant in cirrhosis. In: Italian Journal of Gastroenterology and Hepatology. 1997 ; Vol. 29, No. 3. pp. 262-266.
@article{e0eec3fdf6014602863a68bfd4b9d046,
title = "Efficacy of oral ciprofloxacin as selective intestinal decontaminant in cirrhosis",
abstract = "Background. Selective intestinal decontamination has been proposed to prevent bacterial infection in cirrhosis. Aims. To evaluate the efficacy of ciprofloxacin as selective intestinal decontaminant. Patients and methods. Quantitative microbiological studies on serial faeces were carried out in 15 cirrhotic patients. Ciprofloxacin was given orally at the starting dose of 250 mg every 12 hours for 7 days followed by a single dose of 250 mg/day from day 7 to day 14 and 125 mg/day for the next 3 weeks. Total stool samples were examined in basal conditions and on days 7, 14, 21, 28 and 35 of treatment and 3 and 7 days after treatment withdrawal. Results. Gram-negative flora was completely eliminated in all patients by ciprofloxacin given at doses of 500 and 250 mg/day. When the drug was tapered to 125 mg/day, Escherichia coli reappeared in stools of 7 patients (antibiotic resistant in one patient) and Klebsiella oxytoca in two patients (antibiotic-resistant in one patient). Faecal concentration of Group D Streptococcus was significantly increased at the end of therapy (basal mean 7.7 ± 1.2 log CFU vs post treatment mean 9.6 ± 0.5 log CFU, p <0.05) while the faecal concentration of anaerobic flora and Candida albicans showed no change. Conclusions. Results of this study demonstrate the efficacy of oral ciprofloxacin 250 mg/day is the recommended dose for maintaining Selective Intestinal Decontamination. However, the risks of inducing antibiotic resistance in Gram-positive flora and promoting overgrowth of Gram-positive flora must be carefully considered in all patients chronically treated with oral quinolones.",
keywords = "Ciprofloxacin, Cirrhosis, Intestinal decontamination",
author = "M. Borzio and F. Salerno and M. Saudelli and D. Galvagno and L. Piantoni and L. Fragiacomo",
year = "1997",
language = "English",
volume = "29",
pages = "262--266",
journal = "Digestive and Liver Disease",
issn = "1590-8658",
publisher = "Elsevier B.V.",
number = "3",

}

TY - JOUR

T1 - Efficacy of oral ciprofloxacin as selective intestinal decontaminant in cirrhosis

AU - Borzio, M.

AU - Salerno, F.

AU - Saudelli, M.

AU - Galvagno, D.

AU - Piantoni, L.

AU - Fragiacomo, L.

PY - 1997

Y1 - 1997

N2 - Background. Selective intestinal decontamination has been proposed to prevent bacterial infection in cirrhosis. Aims. To evaluate the efficacy of ciprofloxacin as selective intestinal decontaminant. Patients and methods. Quantitative microbiological studies on serial faeces were carried out in 15 cirrhotic patients. Ciprofloxacin was given orally at the starting dose of 250 mg every 12 hours for 7 days followed by a single dose of 250 mg/day from day 7 to day 14 and 125 mg/day for the next 3 weeks. Total stool samples were examined in basal conditions and on days 7, 14, 21, 28 and 35 of treatment and 3 and 7 days after treatment withdrawal. Results. Gram-negative flora was completely eliminated in all patients by ciprofloxacin given at doses of 500 and 250 mg/day. When the drug was tapered to 125 mg/day, Escherichia coli reappeared in stools of 7 patients (antibiotic resistant in one patient) and Klebsiella oxytoca in two patients (antibiotic-resistant in one patient). Faecal concentration of Group D Streptococcus was significantly increased at the end of therapy (basal mean 7.7 ± 1.2 log CFU vs post treatment mean 9.6 ± 0.5 log CFU, p <0.05) while the faecal concentration of anaerobic flora and Candida albicans showed no change. Conclusions. Results of this study demonstrate the efficacy of oral ciprofloxacin 250 mg/day is the recommended dose for maintaining Selective Intestinal Decontamination. However, the risks of inducing antibiotic resistance in Gram-positive flora and promoting overgrowth of Gram-positive flora must be carefully considered in all patients chronically treated with oral quinolones.

AB - Background. Selective intestinal decontamination has been proposed to prevent bacterial infection in cirrhosis. Aims. To evaluate the efficacy of ciprofloxacin as selective intestinal decontaminant. Patients and methods. Quantitative microbiological studies on serial faeces were carried out in 15 cirrhotic patients. Ciprofloxacin was given orally at the starting dose of 250 mg every 12 hours for 7 days followed by a single dose of 250 mg/day from day 7 to day 14 and 125 mg/day for the next 3 weeks. Total stool samples were examined in basal conditions and on days 7, 14, 21, 28 and 35 of treatment and 3 and 7 days after treatment withdrawal. Results. Gram-negative flora was completely eliminated in all patients by ciprofloxacin given at doses of 500 and 250 mg/day. When the drug was tapered to 125 mg/day, Escherichia coli reappeared in stools of 7 patients (antibiotic resistant in one patient) and Klebsiella oxytoca in two patients (antibiotic-resistant in one patient). Faecal concentration of Group D Streptococcus was significantly increased at the end of therapy (basal mean 7.7 ± 1.2 log CFU vs post treatment mean 9.6 ± 0.5 log CFU, p <0.05) while the faecal concentration of anaerobic flora and Candida albicans showed no change. Conclusions. Results of this study demonstrate the efficacy of oral ciprofloxacin 250 mg/day is the recommended dose for maintaining Selective Intestinal Decontamination. However, the risks of inducing antibiotic resistance in Gram-positive flora and promoting overgrowth of Gram-positive flora must be carefully considered in all patients chronically treated with oral quinolones.

KW - Ciprofloxacin

KW - Cirrhosis

KW - Intestinal decontamination

UR - http://www.scopus.com/inward/record.url?scp=0031444378&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031444378&partnerID=8YFLogxK

M3 - Article

C2 - 9646219

AN - SCOPUS:0031444378

VL - 29

SP - 262

EP - 266

JO - Digestive and Liver Disease

JF - Digestive and Liver Disease

SN - 1590-8658

IS - 3

ER -